Chinese drug regulators completed an expert panel review of a COVID-19 mRNA vaccine co-developed by Fosun Pharma and Germany's BioNTech, and now the shot is in the administrative review stage, according to Fosun.
Caixin
China to use BioNTech vaccine as booster shot, sources say
Joint venture with Fosun Pharma to make 100m to 200m vaccines a month
Fosun Pharma’s joint venture in Shanghai with Germany's BioNTech is expected to reach an annual production capacity of 1 billion doses of COVID-19 vaccine by the end of the year. © Reuters
Read Next
Latest on Caixin
